Press Release

Ref: ADL/SE/2026-27/30 August 1, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400051 BSE CODE: 524348 NSE SYMBOL: AARTIDRUGS Dear Sir/Madam, Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sub: Press Release on Financial Results. Please find attached herewith press release on Financial Results for the Quarter ended June 30, 2026. Kindly take the same on record. Thanking you, Yours faithfully, FOR AARTI DRUGS LIMITED RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M. No.: F12932 Investor Release Q1 FY27 Business & Financial Performance Mumbai, 1st August 2026 Aarti Drugs Limited (Aarti Drugs) (NSE: AARTIDRUGS; BSE:524348), a Mumbai based diversified and fully integrated pharmaceutical company, with interests in Active Pharmaceutical Ingredients (API), Formulation, Specialty Chemicals and Intermediates announced its unaudited Financial Results for the Quarter ended 30th June 2026. Consolidated Financial Highlights Particulars (Rs. Crs.)1 Q1 FY27 Q1 FY26 YoY Q4 FY26 QoQ Total Revenue 703.6 590.8 19% 721.1 -2% Gross Profit 276.0 217.4 27% 270.7 2% EBITDA2 96.9 74.4 30% 96.6 0% EBITDA Margin % 13.8% 12.6% 120 bps 13.4% 40 bps Profit Before Tax (PBT) 69.2 51.1 35% 70.4 -2% PBT Margin % 9.9% 8.7% 120 bps 9.8% 10 bps Profit After Tax (PAT)2,3 50.1 54.03 -7% 55.3 -9% EPS (in Rs.) 5.49 5.91 6.05 1 All figures include Other Income 2 Q1 FY27 EBITDA, PBT and PAT includes an additional ~Rs. 2 crores expense of a CWIP write-off 3 Q1 FY26 PAT includes a principal tax refund of ~Rs.15 crores Consolidated Financial Highlights – Q1 FY27 • Revenue stood at Rs. 703.6 crore as compared to Rs. 590.8 crore in Q1 FY26, reflecting a growth of 19% YoY • EBITDA stood at Rs. 96.9 crore versus Rs. 74.4 crore in Q1 FY26, recording a growth of 30% YoY. EBITDA margin stood at 13.8%, an expansion of 120 bps YoY • PBT stood at Rs. 69.2 crore as against Rs. 51.1 crore, a growth of 35% YoY. PBT margin stood at 9.9%, an expansion of 120 bps YoY • PAT stood at Rs. 50.1 crore as compared to Rs. 54.0 crore in Q1 FY26. Q1 FY26 PAT includes a principal tax refund of ~Rs.15 crores. Excluding this, the growth in PAT would be 29% YoY Segmental Performance Update Particulars (Rs. Crs.) Q1 FY27 Q1 FY26 %YoY Change Q4 FY26 %QoQ Change API 510.4 458.2 11% 551.0 -7% Formulation 86.2 80.3 7% 92.0 -6% Specialty Chemicals 82.6 33.1 150% 56.8 45% Intermediates & Others 24.3 19.2 26% 20.5 19% Investor Release Standalone4 Business Highlights – Q1 FY27 • Revenue stood at Rs. 627.6 crores vs. Rs. 521.3 crores in Q1 FY26, a growth of 20% YoY • Standalone business contributed 89% to the consolidated revenue • 68% of the standalone revenue came from the domestic market and 32% from the exports market • Domestic revenue grew 25% YoY and export revenue grew by 12% YoY • Within the API business, the anti-biotic therapeutic category contributed 35.0%, anti-protozoal 18.5%, anti-inflammatory 11.9%, anti-diabetic 18.2%, antifungal 10.2% and the rest contributed 6.1% to total API sales Formulation4 Segment Highlights • Revenue from formulations stood at Rs. 81.60 crore compared to Rs. 75.8 crore in Q1 FY26, up 8% YoY. Exports contributed 74% to this revenue 4 Includes other income Commenting on the same, Mr. Adhish Patil, CFO & COO, Aarti Drugs Limited said, “We began FY27 with a strong operational and financial performance, driven by a mix of volume growth and improved realizations across our API & Speciality Chemicals portfolio and disciplined execution. The quarter marked a recovery in the pricing environment compared to the previous year, while our continued focus on operational efficiencies and product mix supported profitability. Despite an uncertain and volatile global environment, Aarti Drugs delivered a robust quarter as production across our facilities continued without disruption, reflecting the resilience of our business model. EBITDA increased by 30% YoY to ₹96.9 crore, and EBITDA margins expanded by 120 basis points to 13.8%. Product mix optimization and operational efficiencies strengthened profitability. The demand outlook for our product portfolio looks encouraging. The company's USFDA and UK approvals for facilities remain important growth drivers, supporting expansion in regulated markets. Sayakha continued its planned ramp-up during the quarter, operating at nearly 65% utilization and progressively contributing to our backward integration capabilities. We are also expanding our oral solid dosage (OSD) capabilities through brownfield and adjacent plot developments in Baddi, Himachal Pradesh which is expected to double our production capacity. Operationally, we remain focused on improving capacity utilization, optimizing product mix and enhancing manufacturing efficiencies across our facilities. These initiatives, together with the continued ramp-up of Sayakha, are expected to progressively improve operating leverage and strengthen margin performance over the medium term. Looking ahead, global demand continues to remain resilient, and we aim to enhance ourselves on the regulatory-compliance front to continue to capitalize on opportunities. Alongside this, investments in process optimization, capacity enhancement, backward integration, and operational efficiencies remain a focus.” Investor Release About Aarti Drugs Limited Aarti Drugs Limited was established in the year 1984 and forms part of $6 Billion Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and produces Formulations with its wholly- owned subsidiary-Pinnacle Life Science Private Limited. The Company have total 14 manufacturing facilities out of which 10 manufacturing facilities are in Maharashtra, 3 Manufacturing facilities in Gujarat and 1 Manufacturing facility of Pinnacle is located at Himachal Pradesh. Products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc. For more information, please visit http://www.aartidrugs.com/ Safe Harbor Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors. For more information, please contact Company: Investor Relations (IR) Aarti Drugs Limited Strategic Growth Advisors Pvt. Ltd. CIN: L37060MH1984PLC055433 CIN: U74140MH2010PTC204285 Mr. Rushikesh Deole Mr. Deven Dhruva / Ms. Krisha Shrimankar investorrelations@aartidrugs.com deven.dhruva@sgapl.net / krisha.shrimankar@sgapl.net +91 22 24048199 +91 98333 73300 / +91 87797 99281 http://www.aartidrugs.com/ www.sgapl.net